Canton Strategic Holdings Inc., formerly known as Tharimmune, Inc. until its name change in February 2026, is a diversified company operating in the healthcare and blockchain sectors. Headquartered in Red Bank, New Jersey, the company was incorporated in 2017 and focuses on two primary areas. On the blockchain side, it ...Canton Strategic Holdings Inc., formerly known as Tharimmune, Inc. until its name change in February 2026, is a diversified company operating in the healthcare and blockchain sectors. Headquartered in Red Bank, New Jersey, the company was incorporated in 2017 and focuses on two primary areas. On the blockchain side, it is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton Network. The Canton Network is described as the first privacy-enabled public blockchain, processing $9 trillion in monthly transaction volume. The company's digital asset strategy was initiated through a $545 million private placement in November 2025, which strengthened its balance sheet. In the biotech sector, Canton Strategic Holdings is involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has completed its Phase 1 trial. Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. The management team, led by Chairman and CEO Mark Wendland, brings decades of experience in traditional finance, including repo and treasury operations. As of the latest data, the company has 12 full-time employees, a market capitalization of approximately $146.5 million, and a stock price of $1.90. Financially, the company has no revenue, resulting in negative profit margins, but maintains a strong current ratio of 37.75 and a cash ratio of 36.389. The company's focus on both blockchain and biotech positions it at the intersection of two cutting-edge industries, with the goal of leveraging technology to improve financial markets and healthcare outcomes.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-35.9M
-194.5%
+59.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-93.7M
-759.5%
+70.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.0%
—
—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
5.29x
+243.2%
-58.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
